Organogenesis Holdings Inc. (NASDAQ:ORGO) Stake Boosted by Barclays PLC

Barclays PLC grew its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 251.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 94,809 shares of the company’s stock after acquiring an additional 67,855 shares during the period. Barclays PLC owned 0.07% of Organogenesis worth $271,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Captrust Financial Advisors bought a new stake in Organogenesis in the third quarter worth $36,000. Delap Wealth Advisory LLC acquired a new position in Organogenesis during the 2nd quarter worth $40,000. Intech Investment Management LLC acquired a new position in Organogenesis during the 3rd quarter worth $43,000. Allspring Global Investments Holdings LLC lifted its position in Organogenesis by 4,989.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after acquiring an additional 15,369 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its position in Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after acquiring an additional 9,048 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Gary S. Gillheeney sold 41,052 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $3.52, for a total transaction of $144,503.04. Following the sale, the chief executive officer now directly owns 3,359,726 shares of the company’s stock, valued at $11,826,235.52. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 278,116 shares of company stock valued at $991,190 over the last three months. 36.90% of the stock is owned by insiders.

Organogenesis Stock Up 2.3 %

Organogenesis stock opened at $3.10 on Monday. The firm has a fifty day moving average price of $3.48 and a two-hundred day moving average price of $3.05. The firm has a market cap of $389.75 million, a price-to-earnings ratio of -51.67 and a beta of 1.77. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $115.18 million during the quarter, compared to analyst estimates of $109.59 million. During the same quarter in the prior year, the business posted $0.02 earnings per share. As a group, analysts forecast that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.